Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes

British Journal of Ophthalmology

Volumn 98, Issue 6, 2014, Pages 813-825

  Julien, Sylvie ^a,b   Biesemeier, Antje ^a   Taubitz, Tatjana ^a,b   Schraermeyer, Ulrich ^a,b  

^a Centre for Ophthalmology   (Germany)

^b Preclinical Drug Assessment STZ OcuTox   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; CELL PROTEIN; FC RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMOGLOBIN; PROTEIN HIF1 ALPHA; PROTEIN IBA 1; RANIBIZUMAB; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID CAPILLARY LAYER; CONTROLLED STUDY; ELECTRON MICROSCOPY; FENESTRATION; FLUORESCENCE ANGIOGRAPHY; FLUORESCENCE MICROSCOPY; HYPERTROPHY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; MORPHOMETRICS; NONHUMAN; OPHTHALMOSCOPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA GANGLION CELL; RETINAL THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY;

CHOROID; DRUGS; NEOVASCULARISATION; RETINA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CAPILLARIES; CHOROID; ENDOTHELIUM, VASCULAR; FLUORESCEIN ANGIOGRAPHY; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACACA FASCICULARIS; MICROFILAMENT PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; VIMENTIN;

EID: 84901606839     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304019     Document Type: Article

References (43)

1. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2. (Pubitemid 15204559)
2. D'Amato RJ, Adamis AP. Angiogenesis inhibition in age-related macular degeneration. Ophthalmology 1995;102:1261-2.
3. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol 2012;6:1175-86.
4. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-62. (Pubitemid 27092496)
5. Ryan SJ. Subretinal neovascularization. Natural history of an experimental model. Arch Ophthalmol 1982;100:1804-9. (Pubitemid 12006673)
6. Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 1997;235:313-19.
7. Baffi J, Byrnes G, Chan CC, et al. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 2000;41:3582-9.
8. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-44. (Pubitemid 30641731)
9. Wang F, Rendahl KG, Manning WC, et al. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 2003;44:781-90. (Pubitemid 36159730)
10. Lebherz C, Maguire AM, Auricchio A, et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 2005;54:1141-9. (Pubitemid 40446329)
11. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
12. Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012;227(Suppl 1):2-10.
13. Browning DJ, Kaiser PK, Rosenfeld PJ, et al. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222-6.
14. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70. (Pubitemid 44547437)
15. Ohr M, Kaiser PK. Aflibercept in wet age-related macular degeneration: a perspective review. Ther Adv Chronic Dis 2012;3:153-61.
16. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23. (Pubitemid 351261238)
17. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
18. Schraermeyer U, Julien S. Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes. Expert Opin Biol Ther 2013;13:157-67.
19. Schraermeyer U, Julien S. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol 2012;250:1303-13.
20. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009;7:171-81.
21. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) 2011;25:661-72.
22. Daha NA, Banda NK, Roos A, et al. Complement activation by (auto-) antibodies. Mol Immunol 2011;48:1656-65.
23. Nguyen DC, Scinicariello F, Attanasio R. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics 2011;63:351-62.
24. Hall CE, Slayter HS. The fibrinogen molecule: its size, shape, and mode of polymerization. J Biophys Biochem Cytol 1959;5:11-16.
25. Mojica G, Hariprasad SM, Jager RD, et al. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 2008;92:584. (Pubitemid 351498004)
26. Bunch TJ, Tian B, Seeman JL, et al. Effect of daily prolonged ketamine anesthesia on intraocular pressure in monkeys. Curr Eye Res 2008;33:946-53.
27. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33. (Pubitemid 40270359)
28. Julien S, Biesemeier A, Schraermeyer U. In vitro induction of protein complexes between bevacizumab, VEGF-A165 and heparin: explanation for deposits observed on endothelial veins in monkey eyes. Br J Ophthalmol 2013;97:511-17.
29. Levy DE, Horner AA, Solomon A. Immunoglobulin-sulfated polysaccharide interactions. Binding of agaropectin and heparin by human IgG proteins. J Exp Med 1981;153:883-96. (Pubitemid 11104737)
30. Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013;121:1276-84.
31. Malaise MG, Franchimont P, Mahieu PR. The ability of normal human monocytes to phagocytose IgG-coated red blood cells is related to the number of accessible galactosyl and mannosyl residues in the Fc domain of the anti-red blood cell IgG antibody molecules. J Immunol Methods 1989;119:231-9. (Pubitemid 19132280)
32. Forthal DN, Gach JS, Landucci G, et al. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010;185:6876-82.
33. Saint-Geniez M, Kurihara T, Sekiyama E, et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 2009;106:18751-6.
34. Lang F, Qadri SM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif 2012;33:125-30.
35. Attanasio P, Shumilina E, Hermle T, et al. Stimulation of eryptosis by anti-A IgG antibodies. Cell Physiol Biochem 2007;20:591-600. (Pubitemid 47340619)
36. Hsu SC, Molday RS. Glycolytic enzymes and a GLUT-1 glucose transporter in the outer segments of rod and cone photoreceptor cells. J Biol Chem 1991;266:21745-52. (Pubitemid 121000243)
37. Nihira M, Anderson K, Gorin FA, et al. Primate rod and cone photoreceptors may differ in glucose accessibility. Invest Ophthalmol Vis Sci 1995;36:1259-70.
38. Fliesler SJ, Richards MJ, Miller CY, et al. In vitro metabolic competence of the frog retina: effects of glucose and oxygen deprivation. Exp Eye Res 1997;64:683-92. (Pubitemid 27278295)
39. Winkler BS, Dang L, Malinoski C, et al. An assessment of rat photoreceptor sensitivity to mitochondrial blockade. Invest Ophthalmol Vis Sci 1997;38:1569-77. (Pubitemid 27317853)
40. Zak PP, Kapustina NV, Ostrovskii MA. [High resistance of the rat retina rods to hypoxia]. Ross Fiziol Zh Im I M Sechenova 2001;87:1534-9.
41. Keane PA, Patel PJ, Liakopoulos S, et al. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol 2012;57:389-414.
42. Horn S, Bashan N, Gopas J. Phagocytosis of phenylhydrazine oxidized and G-6-PD-deficient red blood cells: the role of cell-bound immunoglobulins. Blood 1991;78:1818-25.
43. Taylor RP, Horgan C, Hooper M, et al. Dynamics of interaction between complement-fixing antibody/dsDNA immune complexes and erythrocytes. In vitro studies and potential general applications to clinical immune complex testing. J Clin Invest 1985;75:102-11. (Pubitemid 15163973)